These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492 [TBL] [Abstract][Full Text] [Related]
24. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Meric-Bernstam F; Brusco L; Daniels M; Wathoo C; Bailey AM; Strong L; Shaw K; Lu K; Qi Y; Zhao H; Lara-Guerra H; Litton J; Arun B; Eterovic AK; Aytac U; Routbort M; Subbiah V; Janku F; Davies MA; Kopetz S; Mendelsohn J; Mills GB; Chen K Ann Oncol; 2016 May; 27(5):795-800. PubMed ID: 26787237 [TBL] [Abstract][Full Text] [Related]
25. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717 [TBL] [Abstract][Full Text] [Related]
26. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595 [TBL] [Abstract][Full Text] [Related]
27. Pathogenic Germline Mutations in Chinese Patients with Gastric Cancer Identified by Next-Generation Sequencing. Zhou J; Zhao Z; Zhang Y; Bao C; Cui L; Cai S; Bai Y; Shen L; Zhang X Oncology; 2020; 98(8):583-588. PubMed ID: 32521533 [TBL] [Abstract][Full Text] [Related]
28. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. Nicolosi P; Ledet E; Yang S; Michalski S; Freschi B; O'Leary E; Esplin ED; Nussbaum RL; Sartor O JAMA Oncol; 2019 Apr; 5(4):523-528. PubMed ID: 30730552 [TBL] [Abstract][Full Text] [Related]
29. Genomics of lethal prostate cancer at diagnosis and castration resistance. Mateo J; Seed G; Bertan C; Rescigno P; Dolling D; Figueiredo I; Miranda S; Nava Rodrigues D; Gurel B; Clarke M; Atkin M; Chandler R; Messina C; Sumanasuriya S; Bianchini D; Barrero M; Petermolo A; Zafeiriou Z; Fontes M; Perez-Lopez R; Tunariu N; Fulton B; Jones R; McGovern U; Ralph C; Varughese M; Parikh O; Jain S; Elliott T; Sandhu S; Porta N; Hall E; Yuan W; Carreira S; de Bono JS J Clin Invest; 2020 Apr; 130(4):1743-1751. PubMed ID: 31874108 [TBL] [Abstract][Full Text] [Related]
30. Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. Cheng HH; Pritchard CC; Boyd T; Nelson PS; Montgomery B Eur Urol; 2016 Jun; 69(6):992-5. PubMed ID: 26724258 [TBL] [Abstract][Full Text] [Related]
32. Commentary on "Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer". Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Eur Urol. Jun 2016;69(6):992-5. Freedland S; Aronson W Urol Oncol; 2017 Aug; 35(8):536. PubMed ID: 28623073 [TBL] [Abstract][Full Text] [Related]
33. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy. Van Allen EM; Foye A; Wagle N; Kim W; Carter SL; McKenna A; Simko JP; Garraway LA; Febbo PG Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):23-7. PubMed ID: 24366412 [TBL] [Abstract][Full Text] [Related]
34. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. Wu Y; Yu H; Li S; Wiley K; Zheng SL; LaDuca H; Gielzak M; Na R; Sarver BAJ; Helfand BT; Walsh PC; Lotan TL; Cooney KA; Black MH; Xu J; Isaacs WB Eur Urol Oncol; 2020 Apr; 3(2):224-230. PubMed ID: 31948886 [TBL] [Abstract][Full Text] [Related]
35. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families. Vaziri SA; Krumroy LM; Rostai M; Casey G Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249 [TBL] [Abstract][Full Text] [Related]
36. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. Hamel N; Kotar K; Foulkes WD BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837 [TBL] [Abstract][Full Text] [Related]
37. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754 [TBL] [Abstract][Full Text] [Related]
38. BRCA2 germline mutations in Swedish breast cancer families. Chen J; Hedman MZ; Arver BW; Sigurdsson S; Eyfjörd JE; Lindblom A Eur J Hum Genet; 1998; 6(2):134-9. PubMed ID: 9781057 [TBL] [Abstract][Full Text] [Related]
39. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. Agalliu I; Kwon EM; Zadory D; McIntosh L; Thompson J; Stanford JL; Ostrander EA Clin Cancer Res; 2007 Feb; 13(3):839-43. PubMed ID: 17289875 [TBL] [Abstract][Full Text] [Related]
40. Germline pathogenic variants in unselected Korean men with prostate cancer. So MK; Ahn HK; Huh J; Kim KH Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]